Competition and Regulation Issues in the Pharmaceutical Industry [electronic resource] / Organisation for Economic Co-operation and Development
Material type:![Article](/opac-tmpl/lib/famfamfam/AR.png)
Item type | Home library | Collection | Call number | Status | Date due | Barcode | Item holds | |
---|---|---|---|---|---|---|---|---|
Working Paper | Biblioteca Digital | Colección OECD | OECD clp-v4-art10-en (Browse shelf(Opens below)) | Not For Loan |
Collection: Colección OECD Close shelf browser (Hides shelf browser)
No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | ||
OECD clp-11-5kmbpj559n6g The Interface between Competition and Consumer Policies | OECD clp-11-5kmbpj55c8mx Competition Policy for Vertical Relations in Gasoline Retailing | OECD clp-11-5kmbpj55f9jg Energy Security and Competition Policy | OECD clp-v4-art10-en Competition and Regulation Issues in the Pharmaceutical Industry | OECD clp-v4-art10-fr Concurrence et réglementation dans l'industrie pharmaceutique | OECD clp-v4-art11-en The Telecommunications Sector in Russia | OECD clp-v4-art11-fr Le secteur des télécommunications en Russie |
The pharmaceutical sector is a dynamic, research-intensive industry that is fundamentally influenced by a web of regulations designed to a) promote research and innovation in the design and production of drugs, b) protect consumers from potentially harmful effects of drugs, and c) to control public and private expenditure on drugs. These objectives are sometimes in conflict and may require a balancing of the interests of producers and consumers. Since most consumers have some form of health insurance, their incentives to control their purchasers of pharmaceuticals or to purchase from the most efficient pharmacist are limited. Health insurers seek to control pharmaceutial expenditure through various policies such as co-payments, lists of approved drugs and maximum reimbursement levels for different drugs. If reimbursement levels for pharmacists are set at a national or regional level, incentives for entry by new pharmacists are excessive in certain locations, typically leading to restrictions on the establishment of new pharmacies. Wellthought out reform of this industry has the potential to reduce pharmaceutical expenditures while maintaining the quality of the drugs consumed.
There are no comments on this title.